Markus Otto

Summary

Country: Germany

Publications

  1. ncbi Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease
    Markus Otto
    Department of Neurology, University of Goettingen, Germany
    Restor Neurol Neurosci 21:191-209. 2003
  2. ncbi Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study
    M Otto
    Departments of Neurology, University of Goettingen, Germany
    Neurology 62:714-8. 2004
  3. ncbi Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    M Otto
    Neurologische Klinik und Poliklinik, Georg August Universitat Gottingen, Germany
    Neurology 54:1099-102. 2000
  4. ncbi Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease
    M Otto
    Neurologische Klinik und Poliklinik, Georg August Universitat Gottingen, Germany
    Neurology 58:192-7. 2002
  5. ncbi Boxing and running lead to a rise in serum levels of S-100B protein
    M Otto
    Department of Neurology, University Hospital, Gottingen, Germany
    Int J Sports Med 21:551-5. 2000
  6. ncbi Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    J Alzheimers Dis 17:541-51. 2009
  7. ncbi Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:376-82. 2005
  8. ncbi Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease
    Peter Brechlin
    Department of Neurodegeneration and Restorative Research, Center of Neurological Medicine, University of Goettingen, Goettingen, Germany
    Proteomics 8:4357-66. 2008
  9. ncbi Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Department of Neurology, Georg August University Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:164-70. 2005
  10. ncbi Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006

Collaborators

Detail Information

Publications73

  1. ncbi Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease
    Markus Otto
    Department of Neurology, University of Goettingen, Germany
    Restor Neurol Neurosci 21:191-209. 2003
    ..This especially applies to some of the subtypes of CJD and Alzheimer's dementia (AD)...
  2. ncbi Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study
    M Otto
    Departments of Neurology, University of Goettingen, Germany
    Neurology 62:714-8. 2004
    ..As FLU is a clinically safe drug, the authors started a double-blind placebo-controlled study in patients with Creutzfeldt-Jakob disease (CJD)...
  3. ncbi Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    M Otto
    Neurologische Klinik und Poliklinik, Georg August Universitat Gottingen, Germany
    Neurology 54:1099-102. 2000
    ....
  4. ncbi Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease
    M Otto
    Neurologische Klinik und Poliklinik, Georg August Universitat Gottingen, Germany
    Neurology 58:192-7. 2002
    ..Both tests in a larger group of patients with the differential diagnosis of CJD were evaluated...
  5. ncbi Boxing and running lead to a rise in serum levels of S-100B protein
    M Otto
    Department of Neurology, University Hospital, Gottingen, Germany
    Int J Sports Med 21:551-5. 2000
    ..Levels of S-100B protein known to be associated with neuropsychological deficits were not reached in our study. In professional boxing, much higher levels are to be expected and would be worthy of investigation...
  6. ncbi Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    J Alzheimers Dis 17:541-51. 2009
    ....
  7. ncbi Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:376-82. 2005
    ..Similar results were obtained for S-100B. CONCLUSION: We conclude that follow-up investigations and calculation of ratios is a useful tool in the differential diagnosis of CJD. Variations in this pattern were observed in single cases...
  8. ncbi Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease
    Peter Brechlin
    Department of Neurodegeneration and Restorative Research, Center of Neurological Medicine, University of Goettingen, Goettingen, Germany
    Proteomics 8:4357-66. 2008
    ..We conclude that our proteomic approach is useful to differentiate CJD from other neurodegenerative diseases and expect that CSF-optimized 2-D DIGE will find broad application in the search for other brain derived proteins in CSF...
  9. ncbi Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Department of Neurology, Georg August University Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:164-70. 2005
    ..We conclude that more specific markers have to be established for the differentiation of these diseases...
  10. ncbi Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006
    ..These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD...
  11. ncbi Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 6:e23600. 2011
    ..We aimed to test whether soluble fragments of beta-amyloid precursor protein (sAPPα and sAPPß) correlated with clinical subtypes of ALS and were of prognostic value...
  12. ncbi CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
    ..Their distinct molecular phenotypes support the view of different pathophysiological pathways for each of these neurodegenerative diseases...
  13. ncbi Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Ulm, Ulm, Germany
    Dement Geriatr Cogn Disord 23:22-8. 2007
    ..We conclude that this proteomic approach can differentiate CJD from other diseases and may serve as a model for other neurodegenerative diseases...
  14. ncbi TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    Arch Neurol 65:1481-7. 2008
    ..It was demonstrated that different TDP-43 profiles correspond to clinical phenotypes of FTLD or ALS subgroups, and the differential diagnostic potential of TDP-43 was suggested...
  15. ncbi Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    PLoS ONE 4:e7624. 2009
    ..In summary, our findings underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of new culprits for tissue damage in chronic autoimmune demyelination...
  16. ncbi Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel and Georg August University, Gottingen, Germany
    J Neural Transm 118:691-7. 2011
    ..There was no difference in the soluble fractions of brain homogenate in AD and CJD. We therefore conclude that different mechanisms in AD and CJD are responsible for the Aβ1-42 decrease in the CSF...
  17. ncbi iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia
    Stefan Lehnert
    Department of Neurology, University of Ulm, Germany
    Exp Neurol 234:499-505. 2012
    ..However further validation studies need to be done with larger patient cohorts and other proteins need to be checked as well...
  18. ncbi CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease
    Brit Mollenhauer
    Paracelsus Elena Klinik Kassel and Department of Neurology, Georg August University, Gottingen, Germany
    J Alzheimers Dis 24:383-91. 2011
    ..Our results underline the usefulness of the CSF Aβ(1-42%) and Aβ(1-40ox%) as diagnostic biomarkers for AD and DLB, respectively...
  19. ncbi A proteomic approach for the diagnosis of bacterial meningitis
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 5:e10079. 2010
    ..The discrimination of bacterial meningitis (BM) versus viral meningitis (VM) shapes up as a problem, when laboratory data are not equivocal, in particular, when Gram stain is negative...
  20. ncbi ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    J Alzheimers Dis 22:119-28. 2010
    ..Analysis of larger sample cohorts including other diseases with rapid neurodegeneration are required to confirm our findings...
  21. ncbi Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases
    Markus Otto
    Department of Neurology, University of Ulm, Ulm, Germany
    Methods 44:289-98. 2008
    ....
  22. ncbi Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease
    Petra Steinacker
    Department of Neurology, University of Ulm, Germany
    Proteomics 10:81-9. 2010
    ..The selective increase of ubiquitin in CSF of CJD patients might point to an involvement of ubiquitin in pathophysiological process...
  23. ncbi Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 7:e48783. 2012
    ..On the basis of these results, we conclude that differentially sialylated products of Serpin A1 are an interesting biomarker to indicate the development of a dementia during the course of PD...
  24. ncbi Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases
    Petra Steinacker
    Department of Neurology, University Hospital, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    Neurosci Lett 370:36-9. 2004
    ..Our results suggest that H-FABP might be a useful biomarker for the differentiation between the dementias examined if levels in CSF and serum are determined in parallel...
  25. ncbi Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    J Neural Transm 116:1169-78. 2009
    ..We propose to expand this study to larger patient groups comprising followed up cases with known neuropathology...
  26. ncbi Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis
    Petra Steinacker
    Department of Neurology, University of Ulm, Steinhovelstr 1, 89075 Ulm, Germany
    Am J Pathol 176:1409-20. 2010
    ..We propose that Prp has a beneficial role in the SOD1G93A amyotrophic lateral sclerosis mouse model by influencing neuronal and/or glial factors involved in antioxidative defense, rather than anti-apoptotic signaling...
  27. ncbi Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
    Sarah Jesse
    Department of Neurology, University of Ulm, Steinhovelstr 1, 89075, Ulm, Germany
    J Neurol 258:1034-41. 2011
    ..Extensive elevation of routine parameters is not characteristic and should encourage a re-evaluation of the clinical diagnosis...
  28. ncbi Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
    Markus Otto
    Department of Neurology, University of Ulm, Oberer Eselsberg 34, Ulm, Germany
    Amyotroph Lateral Scler 13:1-10. 2012
    ....
  29. ncbi The use of S100B and Tau protein concentrations in the cerebrospinal fluid for the differential diagnosis of bacterial meningitis: a retrospective analysis
    Klaus Jung
    Department of Neurology, University Medical Centre Göttingen, Gottingen, Germany
    Eur Neurol 66:128-32. 2011
    ..To facilitate the differential diagnosis, S100B and Tau protein in the cerebrospinal fluid (CSF) were measured and compared with standard laboratory parameters...
  30. ncbi 2D DIGE of the cerebrospinal fluid proteome in neurological diseases
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Expert Rev Proteomics 7:29-38. 2010
    ..We review the first studies using 2D DIGE for analysis of the CSF proteome in neurological diseases and discuss advantages, as well as drawbacks, of the methodological approach with special emphasis on CSF-related aspects...
  31. ncbi Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes
    Sigurd D Sussmuth
    Department of Neurology, University of Ulm, Ulm, Germany
    Mov Disord 25:1284-8. 2010
    ..In conclusion, this preliminary data show that changes in CSF tau and Abeta1-42 may indicate different protein processing in PSP patients and might, therefore, be relevant in the differentiation of PSP subtypes...
  32. ncbi The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 5:e11986. 2010
    ....
  33. ncbi IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 4:e7638. 2009
    ..We aimed to evaluate the relevance of MRZR to predict conversion of patients with clinically isolated syndrome (CIS) to MS, and to compare it to oligoclonal bands (OCB) and MRI...
  34. ncbi Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease
    B Mollenhauer
    Department of Neurology, Georg August University, Goettingen, Germany
    J Neural Transm 112:933-48. 2005
    ..Follow-up CSF analyses are of limited value for the differentiation of AD and DLB. We conclude that more specific markers have to be established for the differentiation and follow-up of these diseases...
  35. ncbi Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    CNS Neurosci Ther 15:157-82. 2009
    ..In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method...
  36. ncbi Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein
    Petra Steinacker
    Neurologische Klinik und Poliklinik, Georg August Universitat Gottingen, Robert Koch Strasse 40, 37075 Gottingen, Germany
    Mol Cell Biol 25:1339-46. 2005
    ..These results indicate that 14-3-3gamma is unlikely to play a causal role in CJD and related diseases...
  37. ncbi Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis
    Kevin Rostasy
    Department of Pediatrics and Pediatric Neurology, Georg August University, Gottingen, Germany
    J Child Neurol 20:822-5. 2005
    ..These data indicate that axonal injury is not restricted to adult multiple sclerosis but can already occur in children with multiple sclerosis...
  38. ncbi CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
    Mirko Bibl
    Klinik fur Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universitat Duisburg Essen, Essen, Germany
    Proteomics Clin Appl 2:1548-56. 2008
    ..Identifying disease-specific binding properties of affected Aβ carriers may elucidate pathogenic aspects and open up a novel field for therapeutic approaches...
  39. ncbi Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease
    Andreas Meier
    Department of Psychiatry and Psychotherapy, Sleep Disorders Center, Georg August University, Von Siebold Strasse 5, 37075 Goettingen, Germany
    Brain Res 1063:201-3. 2005
    ..All patients of the HD group and eleven patients of the non-HD group showed normal hypocretin-1 levels. Thus, hypocretin-1 may not serve as an additional diagnostic marker for HD...
  40. ncbi Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis
    Katharina Hein Née Maier
    Neurologische Universitatsklinik, Robert Koch Str 40, D 37075 Gottingen, Germany
    Neurosci Lett 436:72-6. 2008
    ..Concerning other biomarkers, we did not observe any changes in the concentrations between groups. Moreover, we did not detect any correlation between Expanded Disability Status Scale (EDSS) and the concentration of investigated proteins...
  41. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
    ..From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD...
  42. ncbi Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy
    J Wiltfang
    Department of Psychiatry, University of Gottingen, Germany
    Metab Brain Dis 14:239-51. 1999
    ..Serum S100beta seems to be a promising biochemical surrogate marker for mild cognitive impairments due to portal-systemic encephalopathy...
  43. ncbi Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Mol Psychiatry 12:671-80. 2007
    ..CSF Abeta peptides may reflect disease-specific impact of distinct neurodegenerative processes on Abeta peptide metabolism and represent a potential diagnostic biomarker for AD, FTD and DLB...
  44. ncbi CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias
    H Schmidt
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 17:204-6. 2004
    ..We conclude that in addition to established CSF parameters, LDH and its isoenzymes might serve as a further help to discriminate between CJD and other dementias...
  45. ncbi Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
    J Wiltfang
    Department of Psychiatry, University of Gottingen, Gottingen, Germany
    J Neurochem 81:481-96. 2002
    ..The severity of dementia was significantly correlated to the fractional Abeta peptide pattern but not to the absolute Abeta peptide concentrations...
  46. ncbi CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    J Neural Transm 113:1771-8. 2006
    ..Combined evaluation of these biomarkers provides a reasonable accuracy for differential diagnosis of AD and DLB...
  47. ncbi 14-3-3 proteins in neurodegeneration
    Petra Steinacker
    Department of Neurology, University of Ulm, Helmholtzstr 8 1, 89081 Ulm, Germany
    Semin Cell Dev Biol 22:696-704. 2011
    ..Here, we review what is currently known of the function of 14-3-3 proteins in nervous tissue focussing on the properties of 14-3-3 proteins important in neurodegenerative disease pathogenesis...
  48. ncbi Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Expert Rev Mol Diagn 8:479-94. 2008
    ..We review recent advances in CSF biomarkers research in CND and thereby focus on markers associated with neurodegeneration...
  49. ncbi Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38
    H Esselmann
    Department of Psychiatry, , , Germany
    Neurodegener Dis 1:236-41. 2004
    ..Therefore, we conclude that there are two independent mechanisms of lithium in intra- and extracellular Abeta peptide production...
  50. ncbi Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis
    Muriel B Sättler
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Am J Pathol 173:1496-507. 2008
    ....
  51. ncbi Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
    A C Ludolph
    Department of Neurology, University of Ulm, Ulm, Germany
    Eur J Neurol 16:297-309. 2009
    ....
  52. ncbi A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis
    Luc Dupuis
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 7:e37885. 2012
    ..Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS)...
  53. ncbi Different binding pattern of antibodies to prion protein on lymphocytes from patients with sporadic Creutzfeldt-Jakob disease
    Peter Ratzka
    Department of Neurology, University Hospital Goettingen, Robert Koch Strasse 40, D 37070 Goettingen, Germany
    Neurosci Lett 343:29-32. 2003
    ..One interpretation of this finding is that lymphocytes patrolling the brain bind and transport PrP(Sc) which has a lower binding affinity for the antibodies directed against physiological PrP...
  54. ncbi Serum tau protein level as a marker of axonal damage in acute ischemic stroke
    Andreas Bitsch
    Department of Neurology, Ruppiner Kliniken GmbH, Neuruppin, Germany
    Eur Neurol 47:45-51. 2002
    ..In conclusion, serum tau protein is a candidate marker of axonal injury. In stroke, its clinical use is limited, because it is detectable only in a proportion of patients...
  55. ncbi Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy
    B J Steinhoff
    Department of Clinical Neurophysiology, Zentrum Neurologische Medizin, Georg August Universitat, Gottingen, Germany
    Epilepsy Res 36:75-82. 1999
    ..We conclude that interictal temporal lobe dysfunction corresponds with neuronal and glial marker elevations in the extracellular space and that site-specific elevations may predict the site of seizure origin biochemically...
  56. ncbi S100B in the cerebrospinal fluid--a marker for glial damage in the rabbit model of pneumococcal meningitis
    H Schmidt
    University of Goettingen, Department of Neurology Department of Medical Psychology and Medical Sociology, Robert Koch Str 40, D 37099 Goettingen, Germany
    Neurosci Lett 475:104-7. 2010
    ..We conclude that the CSF concentration of the glial S100B protein can be used as an additional parameter for future interventional studies focusing on glial cell damage in the rabbit model of bacterial meningitis...
  57. ncbi Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    M Otto
    Department of Neurology, Georg August University Goettingen, Germany
    Neurosci Lett 225:210-2. 1997
    ..We conclude that determination of tau protein levels in CSF is a useful marker for laboratory diagnosis of CJD...
  58. ncbi Unaltered apoptotic behaviour of mononuclear cells from patients with sporadic Creutzfeldt-Jakob disease
    P Ratzka
    Department of Neurology, University of Gottingen, Germany
    J Neurol 248:690-4. 2001
    ..It remains open to question whether this mechanism plays an important role in forms of transmissible encephalopathy other than sporadic CJD, especially after oral transmission...
  59. ncbi Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy (PL, TWG, JMM, JK, JW, University of Erlangen-Nuremberg, Erlangen, Germany
    Biol Psychiatry 55:524-30. 2004
    ..67, p <.01). CONCLUSIONS: We report evidence of three novel amyloid beta peptides that might play an important role in the diagnosis and pathophysiology of Alzheimer's disease...
  60. ncbi Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem Lab Med 44:192-5. 2006
    ..We conclude that more specific markers have to be established to differentiate between these diseases...
  61. ncbi Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Erlangen, Germany
    Neurobiol Aging 29:812-8. 2008
    ..9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance...
  62. ncbi Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Neurodegener Dis 4:366-75. 2007
    ..Heart-type fatty acid-binding protein (H-FABP) was recently discovered in CSF and serum of patients with neurodegenerative diseases...
  63. ncbi Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease
    Katharina Buerger
    Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
    Neurobiol Aging 27:10-5. 2006
    ..Our findings indicate a dissociation in the direction of change in CSF levels of t-tau and p-tau231 in CJD when compared to AD...
  64. ncbi International quality control survey of neurochemical dementia diagnostics
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany
    Neurosci Lett 409:1-4. 2006
    ..Although the results of this quality control survey are promising, the quality of measurements has to be further optimized...
  65. ncbi Electrophoretic separation of amyloid beta peptides in plasma
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, Molecular Neurobiology Lab, University of Erlangen-Nuernberg, Erlangen, Germany
    Electrophoresis 25:3336-43. 2004
    ..Our method can be used to investigate the significance of plasma Abeta peptides in neurodegenerative disorders, and to monitor the efficiency of drugs with beta/gamma-secretase inhibitory potency...
  66. ncbi Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia
    Lienhard Maeck
    Department of Psychiatry and Psychotherapy, , , Germany
    Neurosci Lett 333:33-6. 2002
    ..In all patients Tau protein and S-100B level were slightly elevated, however, Abeta(1-42) was found to be in normal range. Thus, our first results point to PPA being neurochemically linked to frontotemporal degeneration...
  67. ncbi The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Rapid Commun Mass Spectrom 17:1291-6. 2003
    ..We conclude that SELDI-TOF offers a promising tool for dementia expression pattern profiling using a minute amount of a biological sample...
  68. ncbi Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Jens Wiltfang
    Department of Psychiatry, , Germany
    Ann Neurol 54:263-7. 2003
    ..We conclude that the immunoblot shows disease-specific CSF Abeta peptide patterns in CJD and AD and suppose that measurement of the Abeta peptide pattern seems to be a promising diagnostic tool in the differential diagnosis of dementias...
  69. ncbi Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, 91054 Erlangen, Germany
    J Mol Neurosci 23:115-22. 2004
    ..The current literature regarding the physiological and pathological role of phosphorylated Tau proteins is reviewed, as well as the role of these proteins as promising biomarkers in the diagnosis of neurodegenerative disorders...
  70. ncbi Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau
    Piotr Lewczuk
    Molecular Neurobiology Lab, Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Neurobiol Aging 25:273-81. 2004
    ..Presence of the apolipoprotein E 4 allele, age or degree of mental disability did not significantly influence the parameters studied...
  71. ncbi Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides
    Mirko Bibl
    Department of Psychiatry, , , Germany
    Electrophoresis 25:2912-8. 2004
    ..Remarkably, Abeta-SDS-PAGE/immunoblot measured threefold higher levels of Abeta1-42 in CSF than Abeta1-42-ELISA. In summary, our results indicate carrier-mediated epitope masking of Abeta1-42...
  72. ncbi Creutzfeldt-Jakob disease and homocysteine levels in plasma and cerebrospinal fluid
    Stefan Bleich
    Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany
    Gerontology 51:142-4. 2005
    ..These findings provide no evidence for an additional role of homocysteine in the pathogenetic mechanisms underlying CJD neurodegeneration...
  73. ncbi Diagnostic problems during late course in Creutzfeldt-Jakob disease
    Brit Mollenhauer
    J Neurol 250:629-30. 2003